A Phase 4 interventional study of Rotigotine and Placebo in Idiopathic Parkinson's Disease, sponsored by UCB Korea Co., Ltd.. Completed at 29 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-12-18.
Sponsored by UCB Korea Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 6th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 8 in phase 4, and was the 21st registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 8 started in 2012.
This study's enrollment of 380 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Korea Co., Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Korea Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 7th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2012, is one of 7 in phase 4, and was the 26th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.
The study included a maximum 2-week Screening Period, a maximum 4-week Titration Period for early-stage Parkinson's disease or maximum 7-week Titration Period for advanced-stage Parkinson's disease, 8-week Maintenance Period, a maximum 6-day De-escalation Period for early-stage Parkinson's disease or maximum 12-day De-escalation Period for advanced-stage Parkinson's disease and 30-day Safety Follow-Up Period.
The maximum study durations for an individual subject with early-stage Parkinson's disease and with advanced-stage Parkinson's disease were 19 weeks and 23 weeks, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine, daily doses, treatment group
Drug: Rotigotine
Placebo, daily doses, placebo group
Drug: Placebo
Transdermal Patch Content: 2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) * For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period * For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period
Transdermal Patch Size: 10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches
Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)
The HAM-D consists of 17 items. Nine of the items are scored on a 5-point scale, ranging from 0 to 4. The remaining 8 items are scored on a 3-point scale, from 0 to 2. Therefore, the total score ranges between 0 to 52, with a cutoff score of 15/16 diagnosing major depressive disorder.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II)
The Beck Depression Inventory II (BDI-II) is a self-report instrument to measure Depression symptoms and severity. There are 21 items in the BDI-II. Scores of 0-13 are considered minimal depression; 14-19 indicates mild depression; 20-28 indicates moderate depression; and 29-63 indicates severe depression.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale)
The UPDRS Part II is a tool to measure Activities in Daily Living - it includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each of the 13 questions is measured on a scale from 0 (normal) to 4 (severe). The total score of UPDRS part II ranges from 0 (normal) to 52 (severe).
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale)
Improvement of motor symptoms is measured by the change from Baseline in UPDRS Part III motor score. The UPDRS Part III is an accepted and validated scale for the assessment of motor function in Parkinson's disease. Each of the elements in the UPDRS Part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total score of UPDRS part III ranges from 0 (normal) to 108 (severe abnormalities).
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale)
The combined score of UPDRS part II and UPDRS part III is the sum of the individual scores and threfore ranges from 0 (normal) to 160 (severe).
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS)
The AS is an abbreviated version of the Apathy Scale (AS). The AS consists of 14 items phrased as questions that are to be answered on a four-point Likert scale. It was developed specifically for patients with Parkinson Disease (PD). For questions 1-8, the scoring system is the following: not at all = 3 points; slightly = 2 points; some =1 point, a lot = 0 point. For questions 9-14: the scoring system is the following: not at all = 0 points; slightly = 1 point; some = 2 points; a lot = 3 points. Adding all scores provides the final score with a range from 0 to 42.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS)
The SHAPS is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores ranges from 0 to 14. A higher score represents more anhedonic symptoms.
Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
This double-blind, randomized, multicenter, placebo-controlled, in-Patient study started recruiting in April 2012.
| Milestone | Rotigotine | Placebo |
|---|---|---|
| Started | 184 | 196 |
| Completed | 149 | 164 |
| Not completed | 35 | 32 |
| Withdrew: Adverse event | 25 | 16 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 8 |
| Withdrew: Other reason | 0 | 2 |
The HAM-D consists of 17 items. Nine of the items are scored on a 5-point scale, ranging from 0 to 4. The remaining 8 items are scored on a 3-point scale, from 0 to 2. Therefore, the total score ranges between 0 to 52, with a cutoff score of 15/16 diagnosing major depressive disorder.
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D) | -4.79 (-5.87 to -3.71) | -3.68 (-4.68 to -2.67) |
The Beck Depression Inventory II (BDI-II) is a self-report instrument to measure Depression symptoms and severity. There are 21 items in the BDI-II. Scores of 0-13 are considered minimal depression; 14-19 indicates mild depression; 20-28 indicates moderate depression; and 29-63 indicates severe depression.
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of Beck Depression Inventory (BDI-II) | -5.87 (-7.39 to -4.34) | -4.68 (-6.11 to -3.26) |
The UPDRS Part II is a tool to measure Activities in Daily Living - it includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each of the 13 questions is measured on a scale from 0 (normal) to 4 (severe). The total score of UPDRS part II ranges from 0 (normal) to 52 (severe).
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living-ADL Subscale) | -1.13 (-1.76 to -0.50) | -0.10 (-0.69 to 0.49) |
Improvement of motor symptoms is measured by the change from Baseline in UPDRS Part III motor score. The UPDRS Part III is an accepted and validated scale for the assessment of motor function in Parkinson's disease. Each of the elements in the UPDRS Part III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total score of UPDRS part III ranges from 0 (normal) to 108 (severe abnormalities).
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Subscale) | -3.07 (-4.28 to -1.86) | -1.65 (-2.78 to -0.52) |
The combined score of UPDRS part II and UPDRS part III is the sum of the individual scores and threfore ranges from 0 (normal) to 160 (severe).
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Combined Score of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (ADL) Plus Part III (Motor Subscale) | -4.20 (-5.79 to -2.62) | -1.81 (-3.29 to -0.33) |
The AS is an abbreviated version of the Apathy Scale (AS). The AS consists of 14 items phrased as questions that are to be answered on a four-point Likert scale. It was developed specifically for patients with Parkinson Disease (PD). For questions 1-8, the scoring system is the following: not at all = 3 points; slightly = 2 points; some =1 point, a lot = 0 point. For questions 9-14: the scoring system is the following: not at all = 0 points; slightly = 1 point; some = 2 points; a lot = 3 points. Adding all scores provides the final score with a range from 0 to 42.
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of Apathy Scale (AS) | -1.93 (-2.83 to -1.04) | -0.67 (-1.50 to 0.17) |
The SHAPS is a self-report instrument developed for the assessment of hedonic capacity. The sum of the 14 items scores ranges from 0 to 14. A higher score represents more anhedonic symptoms.
| units on a scale | Efficacy Evaluable Set (Rotigotine Treated Subjects) | Efficacy Evaluable Set (Placebo Treated Subjects) |
|---|---|---|
| Change From Baseline to the End of Maintenance Period in the Score of Snaith-Hamilton Pleasure Scale (SHAPS) | -0.82 (-1.28 to -0.37) | -0.60 (-1.03 to -0.17) |
Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study, which began in April 2012 and concluded in October 2014.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 6/184 (3.3%) | 112/184 (60.9%) |
| Placebo | — | 14/196 (7.1%) | 91/196 (46.4%) |
| Event | Rotigotine | Placebo |
|---|---|---|
| Jaw fractureInjury, poisoning and procedural complications | 0/184 | 2/196 |
| SpondylolisthesisCongenital, familial and genetic disorders | 1/184 | 0/196 |
| HepatitisHepatobiliary disorders | 1/184 | 0/196 |
| JaundiceHepatobiliary disorders | 1/184 | 0/196 |
| Kidney transplant rejectionImmune system disorders | 1/184 | 0/196 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/184 | 0/196 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/184 | 0/196 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/184 | 0/196 |
| DizzinessNervous system disorders | 1/184 | 0/196 |
| TremorNervous system disorders | 1/184 | 0/196 |
| Event | Rotigotine | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 42/184 | 15/196 |
| DizzinessNervous system disorders | 28/184 | 25/196 |
| Suicidal ideationPsychiatric disorders | 21/184 | 22/196 |
| Application site pruritusGeneral disorders | 19/184 | 10/196 |
| HeadacheNervous system disorders | 19/184 | 20/196 |
| VomitingGastrointestinal disorders | 13/184 | 2/196 |
| InsomniaPsychiatric disorders | 13/184 | 6/196 |
| NasopharyngitisInfections and infestations | 7/184 | 13/196 |
| PruritusSkin and subcutaneous tissue disorders | 12/184 | 2/196 |
| Application site erythemaGeneral disorders | 11/184 | 5/196 |
Baseline Characteristics refer to the Randomized Set (RS), which consists of all randomized subjects.
| Age, Continuous(years) | Rotigotine | Placebo | Total Title |
|---|---|---|---|
| Mean | 65.6 ± 8.9 | 64.9 ± 8.2 | 65.2 ± 8.5 |
| Age, Customized(participants) | Rotigotine | Placebo | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| >18-<65 years | 76 | 88 | 164 |
| >=65 years | 108 | 108 | 216 |
| Sex: Female, Male(Participants) | Rotigotine | Placebo | Total Title |
|---|---|---|---|
| Female | 96 | 122 | 218 |
| Male | 88 | 74 | 162 |
| Weight(kg) | Rotigotine | Placebo | Total Title |
|---|---|---|---|
| Mean | 61.54 ± 9.68 | 62.24 ± 9.84 | 61.90 ± 9.76 |
| Height(cm) | Rotigotine | Placebo | Total Title |
|---|---|---|---|
| Mean | 160.04 ± 8.41 | 159.17 ± 8.14 | 159.59 ± 8.27 |
The record gives a start of Apr 2012, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine